“Yes, so first of all, on CAS, cryo will become less and less part of the mix, but I think that rate of decline will slow and then that will really aid in the growth of that business going forward.”

In context

“rm. The next couple of -- maybe, I don't know if it will exactly happen in the fiscal year, but we're in that ballpark and really excited about it. Danielle Antalffy: That's so helpful. Thanks so much. Ryan Weispfenning: Thank you, Danielle. Let's take the last question, please, Wynne. Operator: Our last question comes from Shagun Singh at RBC. Shagun Singh: Great. Thank you so much. So, a couple of follow-ups on the CAS business. Impressive growth. Can you talk about the mix of cryo? It seems like it's becoming less and less of a headwind. Any color on pricing there? And then on RDN, any updated thoughts on what patient subset you think you could get coverage for? Thank you for taking the questions. Geoff Martha: Sean, do you want to take the first one? Sean Salmon: Sure, thanks, Shagun. Yes, so first of all, on CAS, cryo will become less and less part of the mix, but I think that rate of decline will slow and then that will really aid in the growth of that business going forward. It's still a really valued tool and particularly in places that don't use general anesthesia and are more cost-constrained. It really is holding up very, very well. So, I think it hits kind of a near nadir and it'll stay there and then we'll have growth on top of that. With regard to your question on what we're expecting for coverage with the population of patients, I think what I'd just say is, I will front run the CMS decision makers here, but what we've been presenting to them is what is the evidence and what are the guidelines and professional society saying. And those really track pretty closely. So, to meet the standard of reasonable and necessary for CMS, I think it's going to be very close to what we've studied and what's being recommended by the guidelines. And that would be pati”